Due to the COVID-19 pandemic, our 28th Annual congress will take place virtually.
Invited speakers across plenary, parallel and keynote sessions represent the leading individuals and labs active in the field today. Our congresses have become known for their cutting-edge science, up-to-date programming, student engagement activities, and their focus on enabling in-depth networking and collaborations across our exhibition and poster sessions. We will endeavour to reproduce as much of this as we can in our virtual event, hoping you will enjoy and benefit from this different event until we meet again in 2022.
Although we have attracted new collaborators annually, 80% of our sponsor base work with us year on year, with some having been our partners for over 11 years. We strive to balance academic excellence and open discourse with opportunity for industry and academia to network in a comfortable and casual setting.
For detailed statistics on all previous congresses, please refer to our website but, as this is our first virtual event, we are not sure of the impact this will have on registrations: https://www.esgct.eu/Events/Previous-Events.aspx. If you are interested in sponsoring this event you can find the details on our different packages in our brochure.
Non-viral genetic therapy strategies for the treatment of ataxia telangiectasia
James Grey received the ESGCT-sponsored prize for best poster presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about his winning presentation here!
Gene therapy for thrombotic thrombocytopaenic purpura
Robyn Bell received the ESGCT-sponsored prize for best oral presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about her winning presentation here!
CRISPR-Cas9 genome editing - molecular scissors a bit too sharp?
Grégoire Cullot received the ESGCT-sponsored prize for best oral presentation at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about his winning presentation here!
Dgkk as a new therapeutic target in the Fmr1-KO murine model of Fragile X
Karima Habbas received the ESGCT-sponsored prize for best poster at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about her winning presentation here!